Eli Lilly and Company

Advisor - Fragment-based Computational Design

San Diego, California, United States

Not SpecifiedCompensation
Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceutical Research, BiotechnologyIndustries

Requirements

Candidates should possess a Ph.D. in a relevant scientific discipline, such as computational chemistry, bioinformatics, or a related field, and demonstrate a strong background in cheminformatics, molecular modeling, and fragment-based drug discovery. Experience with structure-based drug design, molecular dynamics simulations, and machine learning techniques is highly desirable.

Responsibilities

The Computational Scientist will utilize state-of-the-art software to grow, link, and merge fragment hits into novel chemical designs, collaborating with informaticians to develop improved methods for this process. They will triage and analyze data from various experiments, including SPR, NMR, crystallography, and cryo-EM, to generate actionable hypotheses, and contribute to the overall transformation of fragment-based lead discovery through the integration of computational tools and techniques.

Skills

Cheminformatics
Molecular Modeling
Fragment-based Drug Discovery
Structure-based Drug Design
Molecular Dynamics Simulations
Machine Learning
SPR
NMR
Crystallography
Cryo-EM

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Key Metrics

Indianapolis, IndianaHeadquarters
1876Year Founded
$1,180.1MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.
Potential construction delays in Indiana could affect GLP-1 drug production timelines.
Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.
Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.
FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.
Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.
Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI